#10/2.25

Docket No.: GNCA-P03-007

Group Art Unit: 1632

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Beach et al

Application No.: 10/055797

Filed: January 22, 2002 Examiner: LACOURCIERE, Karen

For: METHODS AND COMPOSITIONS FOR

RNA INTERFERENCE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached. It is noted that the published Canadian application (in English) corresponding to WO 00/44895 was provided to the Examiner in an interview on 17 June 2003.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.



7 300

Docket No.: GNCA-P03-007

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GNCA-P03-007.

Dated: 7-1-03

Respectfully submitted,

Reg tration No.: 36,709, ROPES & GRAY LLP One International Place Boston, Massachusetts 02110-2624 (617) 951-7000 (617) 951-7050 (Fax)

Attorneys/Agents For Applicant

#10

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031 U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
000	Sociate for form 14 vor vi			Application Number	10/055797		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			SCLOSURE	Filing Date	January 22, 2002 David Beach		
			PPLICANT	First Named Inventor			
	3 ,,,, 2 ,,,, 2 ,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1632	$\frac{0}{2}$	
	(use as many sheets as necessary)			Examiner Name	LACOURCIERE, Karen	٠	
Sheet	1	of	1	Attorney Docket Number	GNCA-P03-007	;	

			NT DOCUMENTS	
Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA	6,506,559	01-14-2003	Fire et al.	C
_	No.1	Cite No. 1 Number-Kind Code ² (if known)	Cite No.1 Number-Kind Code² (if known) MM-DD-YYYY	No. Number-Kind Code ² (if known)

		FOREI	GN PATENT D	OCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
	AB	WO 94/01550	01-20-1994	Hybridon, Inc		
	AC	WO 00/63364	10-26-2000	American Home Products		
	AD	WO 00/44895	08-03-2000	RiboPharma AG		
	AE	WO 99/49029	09-30-1999	Dept. of Primary Industries		
	AF	WO 00/01846	01-13-2000	Devgen N.V.		
	AG	WO 00/44914	08-03-2000	University of Georgia		
	AH	WO 01/49844	07-12-2001	Rutgers University		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	r Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	Al	Singh et al. "Inverted-repeat DNA: a new gene-silencing tool for seed lipid modification" Biochem Soc Trans 28(6):925 (2000)				
	AJ	Hammond et al. "Post-transcriptional gene silencing by double-stranded RNA" Nature Rev Genetics 2(2):10 (2001)				
	AK	Piccin et al. "Efficient and heritable functional knock-out of an adult phenotype in Drosophila using a GAL4-driven hairpin RNA incorporating a heterologous spacer" <i>Nuc Acid Res</i> 29(12):E55 (2001)				

Examiner	Date	
Signature	Considered	